Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	425637-18-9
Formula :	C₂₅H₂₂N₆O₂
M.W :	438.48
SMILES Code :	O=C(C(C1=CNC2=C1C=CC=C2)=C3C4=C5C=CC=CC5=NC(N6CCN(C)CC6)=N4)NC3=O
Synonyms :	AEB071
MDL No. :	MFCD16038049
InChI Key :	OAVGBZOFDPFGPJ-UHFFFAOYSA-N
Pubchem ID :	10296883

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H317
Precautionary Statements:	P280

GNAQ mutant cells	0-1000 nM	24 hours	AEB071 inhibited phosphorylation of the PKC substrate p-MARCKS and pS6, and also inhibited ERK phosphorylation in GNAQ mutant cells, but no ERK inhibition was observed in GNA11 mutant and wild-type cells.	PMC4146424
JURKAT	5 μM	3 days	To evaluate the effect of sotrastaurin on GSI resistant cells, the results showed that sotrastaurin significantly reduced the phosphorylation of P-S6.	PMC8097059
MOLT-3	5 μM	3 days	To evaluate the effect of sotrastaurin on GSI resistant cells, the results showed that sotrastaurin significantly reduced the phosphorylation of P-S6.	PMC8097059
N2a cells	300 nM	48 hours	Inhibited DJ-1 deficiency-induced MAO-B expression	PMC10545772
GNAQ/GNA11-mutant cells	0-2 μM	5 days	AEB071 showed dose-dependent inhibition of proliferation in GNAQ/GNA11-mutant cells with GI50 values ranging from 250-500nM, while no inhibition was observed in wild-type cells.	PMC4146424
DND-41	5 μM	5 days	To evaluate the effect of sotrastaurin on GSI resistant cells, the results showed that sotrastaurin significantly reduced the phosphorylation of P-S6.	PMC8097059
PEER	5 μM	5 days	To evaluate the effect of sotrastaurin on GSI resistant cells, the results showed that sotrastaurin significantly reduced the phosphorylation of P-S6.	PMC8097059

nu/nu SCID mice	GNAQ mutant xenograft model	Oral	AEB071: 80mg/kg/d, BYL719: 50mg/kg/d	5 days/week for 2 weeks	The combination therapy of AEB071 and BYL719 significantly inhibited tumor growth in the GNAQ mutant xenograft model, with a significant reduction in tumor volume compared to either drug alone.	PMC4146424
NOD/SCID mice	PDTALL19 xenograft model	intraperitoneal injection	40 mg/kg	5 days on/2 days off, for 15 days	To evaluate the effect of sotrastaurin in combination with GSI on PDTALL19 xenograft model, the results showed that the combination treatment significantly prolonged survival and reduced leukemic burden in mice.	PMC8097059

{[proInfo.proName]}

CAS No.: 425637-18-9

{[proInfo.proName]}

CAS No.: 425637-18-9

Alternative Products

Product Details of Sotrastaurin

Safety of Sotrastaurin

Related Pathways of Sotrastaurin

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00409929	Healthy	PHASE1	COMPLETED	-	Novartis Investigative Site, B... More >>ern, Switzerland Less <<
NCT01430416	Uveal Melanoma	PHASE1	COMPLETED	2019-05-22	Dana Farber Cancer Institute D... More >>FCI - Brookline, Boston, Massachusetts, 02215, United States\|Memorial Sloan Kettering MSKCC 4, New York, New York, 10017, United States\|Novartis Investigative Site, Paris, 75231, France\|Novartis Investigative Site, Leiden, 2300 RC, Netherlands\|Novartis Investigative Site, London, SW3 6JJ, United Kingdom Less <<
NCT00545259	de Novo Liver Transplantation	PHASE1	COMPLETED	-	Novartis investigative site, B... More >>erlin, Germany\|Novartis Investigative Site, Padova, Italy\|Novartis investigative site, Zurich, Switzerland Less <<
NCT00492869	Kidney Transplantation	PHASE1\|PHASE2	COMPLETED	-	USC Medical Center, Los Angele... More >>s, California, 90033, United States\|University of California San Diego, San Diego, California, 92103-8401, United States\|California Pacific Medical Center, San Francisco, California, 94115, United States\|UCSF, San Francisco, California, 94143, United States\|University of Colorado Health Science Center, Denver, Colorado, 80262, United States\|Lifelink, Inc., Tampa, Florida, United States\|U of Maryland Medical Center, Baltimore, Maryland, United States\|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States\|Brigham and Women's Hospital, Boston, Massachusetts, United States\|University of Michigan Health System, Ann Arbor, Michigan, United States\|Henry Ford Hospital Transplant Institute, Detroit, Michigan, United States\|Saint Barnabas Medical Center, Livingston, New Jersey, 07039, United States\|Mount Sinai Medical Center, New York, New York, 10029, United States\|Comprehensive Transplant Clinic, New York, New York, United States\|Duke University Medical Center, Durham, North Carolina, United States\|University of Cincinnati, Dept of Internal Medicine, Cincinnati, Ohio, United States\|University of Toledo Health Science Campus, Toledo, Ohio, United States\|University of Pennsylvania Health System-Presbyterian Medical Center, Philadelphia, Pennsylvania, 19104, United States\|Baylor U Medical Center, Dallas, Texas, United States\|University of Texas Medical Branch at Galveston, Galveston, Texas, 77555 - 0561, United States\|University of Utah, Salt Lake City, Utah, United States\|U of Wisconsin Hospital Clinics, Madison, Wisconsin, United States\|Medical College of Wisconsin, Milwaukee, Wisconsin, United States\|CHU Erasme, Bruxelles, Belgium\|UZ Gasthuisberg, Leuven, Belgium\|Saint Joseph's Hospital, Hamilton, Ontario, Canada\|Queen Elizabeth II, Halifax, Canada\|Hopital Maisonneuve-Rosemont, Montreal Quebec, Canada\|Klinikum der Humboldt Universitat Charite, Berlin, Germany\|Universitaetsklinik Charité, Berlin, Germany\|Medizinische Hochschule Hannover, Hannover, Germany\|Univ.-Klinikum Heidelberg, Heidelberg, Germany\|Staedt. Kliniken Koeln-Merheim, Koeln, Germany\|Klinikum der Universitaet Regensburg, Regensburg, Germany\|Fundacion Puigvert, Barcelona, Spain\|Hospital Juan Canalejo, La Coruna, Spain\|Enheten f Transpl och Leverkir, SU/Sahlgrenska, Goteborg, Sweden\|Transplantationskirurgiska mottagningen, Akademiska Sjukhuse, Uppsala, Sweden\|Addenbrookes Hospital, Cambridge, United Kingdom\|Leicester General Hospital, Leicester, United Kingdom\|Churchill Hospital, Oxford, United Kingdom Less <<
NCT00615693	Uveitis\|Posterior Uveitis\|Panu... More >>veitis Less <<	PHASE2	COMPLETED	-	University of Southern Califor... More >>nia Doheny Eye Institute, Los Angeles, California, 90033, United States\|University of California, San Francisco, California, 94143, United States\|Colorado Retina Associates, Denver, Colorado, 80230, United States\|University of Miami Miller School of Medicine; Anne Bates Leach Eye Hosptial;Bascom Palmer Eye Institute, Miami, Florida, 33136, United States\|University of South Florida, Eye Institute, Tampa, Florida, 33612, United States\|Emory University, Atlanta, Georgia, 30322, United States\|John Hopkins Hospital/Wilmer Eye Institute, Baltimore, Maryland, 21287, United States\|MERSI, Cambridge, Massachusetts, 02142, United States\|Mayo Clinic Department of Opthalmology, Rochester, Minnesota, 55905, United States\|Cornea and Laser Eye Institute, Teaneck, New Jersey, 07666, United States\|New York Eye and Ear Infirmary, Clinical Research Department, New York, New York, 10003, United States\|Retina Research Centre, Austin, Texas, 78705, United States\|Vitreoretinal Consultants, Houston, Texas, 77030, United States Less <<
NCT00416546	Healthy	PHASE1	COMPLETED	2025-10-07	Novartis Investigative Site, D... More >>orval, Quebec, Canada Less <<
NCT01402440	Diffuse Large B-Cell Lymphoma	PHASE1	TERMINATED	2025-04-14	City of Hope National Medical ... More >>Center, Duarte, California, 91010-3000, United States\|Washington University School of Medicine Div. of Medical Oncology, Saint Louis, Missouri, 63110, United States\|Hackensack University Medical Center Hackensack (SC), Hackensack, New Jersey, 07601, United States\|Memorial Sloan Kettering Cancer Center MSK 2, New York, New York, 10021, United States\|Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, 43210, United States\|University of Texas/MD Anderson Cancer Center SC Location, Houston, Texas, 77030-4009, United States\|Novartis Investigative Site, Creteil, 94010, France\|Novartis Investigative Site, Lille Cedex, 59 037, France\|Novartis Investigative Site, Pierre-Benite Cédex, F-69495, France\|Novartis Investigative Site, Rouen Cedex 1, 76038, France\|Novartis Investigative Site, Berlin, 13353, Germany\|Novartis Investigative Site, Muenchen, 81377, Germany\|Novartis Investigative Site, Shatin, New Territories, Hong Kong\|Novartis Investigative Site, Milano, MI, 20133, Italy\|Novartis Investigative Site, Torino, TO, 10126, Italy\|Novartis Investigative Site, Seoul, Korea, 135-710, Korea, Republic of\|Novartis Investigative Site, Amsterdam, 1066 CX, Netherlands\|Novartis Investigative Site, Groningen, 9713 GZ, Netherlands\|Novartis Investigative Site, Rotterdam, 3015 CE, Netherlands\|Novartis Investigative Site, Rotterdam, 3075 EA, Netherlands\|Novartis Investigative Site, Barcelona, Catalunya, 08003, Spain\|Novartis Investigative Site, Barcelona, 08025, Spain\|Novartis Investigative Site, Taipei, 10048, Taiwan\|Novartis Investigative Site, Manchester, M20 2BX, United Kingdom Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.28mL 0.46mL 0.23mL	11.40mL 2.28mL 1.14mL	22.81mL 4.56mL 2.28mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed